Cristin

2021
1.	Juraleviciute, Marina; Nsengimana, Jérémie; Newton-Bishop, Julia; Hendriks, Gert J.; Slipicevic, Ana. MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy. Cancer Medicine 2021 ;Volum 10.(8) s. 2840-2854 OUS UiO Untitled
2019
2.	Juraleviciute, Marina; Pozniak, Joanna; Nsengimana, Jérémie; Harland, Mark; Randerson-Moor, Juliette; Vernhoff, Patrik; Bassarova, Assia Vassileva; Øy, Geir Frode; Trøen, Gunhild; Flørenes, Vivi Ann; Bishop, David Timothy; Herlyn, Meenhard; Newton-Bishop, Julia; Slipicevic, Ana. MX 2 is a novel regulator of cell cycle in melanoma cells. Pigment Cell & Melanoma Research 2019 OUS Untitled
2018
3.	Wang, Zhihui; Førsund, Mette S; Tropé, Claes Gøran; Nesland, Jahn M; Holm, Ruth; Slipicevic, Ana. Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro. Cancer Medicine 2018 ;Volum 7.(8) s. 3955-3964 OUS UiO Untitled
2017
4.	Li, Xiaoran; Lu, Jie; Kan, Quancheng; Li, Xiaoli; Fan, Qiong; Li, Yaqing; Huang, Ruixia; Slipicevic, Ana; Dong, Phuc Hiep; Eide, Lars; Wang, Junbai; Zhang, Hongquan; Berge, Viktor; Goscinski, Mariusz Adam; Kvalheim, Gunnar; Nesland, Jahn M; Suo, Zhenhe. Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells. Scientific Reports 2017 ;Volum 7:5081. s. 1-20 OUS UiO Untitled
2016
5.	Nymoen, Dag Andre; Slipicevic, Ana; Holth, Arild; Emilsen, Elisabeth; Falkenthal, Thea Eline Hetland; Tropé, Claes Gøran; Reich, Reuven; Flørenes, Vivi Ann; Davidson, Ben. Mir-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma. Human Pathology 2016 ;Volum 54. s. 74-81 UiO OUS Untitled
2015
6.	Flørenes, Vivi Ann; Emilsen, Elisabeth; Dong, Phuc Hiep; Førsund, Mette S; Holm, Ruth; Slipicevic, Ana. Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma. Cancer Medicine 2015 ;Volum 4.(6) s. 903-913 OUS Untitled

7.	Magnussen, Gry Irene; Emilsen, Elisabeth; Fleten, Karianne Giller; Engesæter, Birgit Øvstebø; Nahse-Kumpf, Viola; Fjær, Roar; Slipicevic, Ana; Flørenes, Vivi Ann. Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma. BMC Cancer 2015 ;Volum 15:462. OUS Untitled

8.	Wang, Zhihui; Slipicevic, Ana; Førsund, Mette S; Tropé, Claes Gøran; Nesland, Jahn M; Holm, Ruth. Expression of CDK1Tyr15, pCDK1 Thr161, cyclin B1 (Total) and pCyclin B1 Ser126 in vulvar squamous cell carcinoma and their relations with clinicopatological features and prognosis. PLOS ONE 2015 ;Volum 10.(4) OUS UiO Untitled
2014
9.	Slipicevic, Ana; Holth, Arild; Hellesylt, Ellen; Tropé, Claes Gøran; Davidson, Ben; Flørenes, Vivi Ann. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.. Gynecologic Oncology 2014 ;Volum 135.(1) s. 118-124 OUS UiO Untitled

10.	Slipicevic, Ana; Somasundaram, Rajasekharan; Sproesser, Katrin; Herlyn, Meenhard. Isolation of melanoma cell subpopulations using negative selection. Methods in molecular biology 2014 ;Volum 1102. s. 501-512 OUS Untitled
2013
11.	Slipicevic, Ana; Øy, Geir Frode; Rosnes, Anne Katrine Ree; Stakkestad, Øystein; Emilsen, Elisabeth; Engesæter, Birgit Øvstebø; Mælandsmo, Gunhild; Flørenes, Vivi Ann. Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis. Cancer Biology & Therapy 2013 ;Volum 14.(2) s. 146-154 OUS Untitled
2012
12.	Magnussen, Gry Irene; Holm, Ruth; Emilsen, Elisabeth; Rosnes, Anne Katrine Ree; Slipicevic, Ana; Flørenes, Vivi Ann. High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy. PLOS ONE 2012 ;Volum 7.(6) s. - OUS Untitled

13.	Slipicevic, Ana; Herlyn, Meenhard. Narrowing the knowledge gaps for melanoma. Uppsala Journal of Medical Sciences 2012 ;Volum 117.(2) s. 237-243 OUS Untitled

14.	Slipicevic, Ana; Holm, Ruth; Emilsen, Elisabeth; Rosnes, Anne Katrine Ree; Welch, Danny R.; Mælandsmo, Gunhild; Flørenes, Vivi Ann. Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival. BMC Cancer 2012 ;Volum 12. s. - OUS UiT Untitled
2010
15.	Slipicevic, Ana. Studies of the PI3K/Akt and MAPK/ERK1/2 signaling pathways: identification of novel downstream targets involved in development and progression of melanoma. Unipub forlag 2010 (ISBN 978-82-8072-599-8) 68 s. OUS UiO Untitled

16.	Slipicevic, Ana; Øy, Geir Frode; Engesæter, Birgit Øvstebø; Mælandsmo, Gunhild; Flørenes, Vivi Ann. Sensitization of melanoma cells to TRAIL-R2 agonist antibody by low-dose anisomycin. European Journal of Cancer 2010 ;Volum 8.(5) s. 69-69 OUS Untitled

17.	Øy, GF; Slipicevic, Ana; Davidson, Ben; Faye, Ragnar Solberg; Mælandsmo, Gunhild; Flørenes, Vivi Ann. Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma. International Journal of Cancer 2010 ;Volum 126.(2) s. 350-361 OSLOMET UiO OUS Untitled
2009
18.	Slipicevic, Ana; Oy, GF; Askildt, IC; Holth, Arild; Hellesylt, E.; Flørenes, Vivi Ann; Davidson, Ben. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions. Human Pathology 2009 ;Volum 40.(4) s. 527-537 UiO OUS Untitled
2008
19.	Slipicevic, Ana; Jørgensen, Kjersti; Skrede, Martina; Rosnes, Anne Katrine Ree; Trøen, Gunhild; Davidson, Ben; Flørenes, Vivi Ann. The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells. BMC Cancer 2008 ;Volum 8. s. - UiO OUS Untitled

20.	Torlakovic, EE; Slipicevic, Ana; Flørenes, Vivi Ann; Chibbar, R; DeCoteau, JF; Bilalovic, N. Fli-1 expression in malignant melanoma. Histology and Histopathology 2008 ;Volum 23. s. 1309-1314 UiO Untitled
2006
21.	Torlakovic, Emina; Slipicevic, Ana; Robinson, Chris; Chibbar, Rajni; DeCoteau, John F; Alfsen, G. Cecilie; Flørenes, Vivi Ann. Pax-5 Expression in nonhematopoietic tissues.. American Journal of Clinical Pathology 2006 ;Volum 126.(5) s. 798-804 OUS Untitled